BACKGROUND: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract that significantly impacts the health-related quality of life (HR-QOL). A decreased HR-QOL has been demonstrated in patients with active disease compared with patients in remission. In this cross-sectional study, we examined the role of depression and disease activity as independent factors in predicting patient's HR-QOL. METHODS: Hundred and five patients with either Crohn's disease (CD) or ulcerative colitis (UC) were enrolled. Disease activity was evaluated using Crohn's Disease Activity Index or Seo's Activity Index. Depressive symptoms were evaluated using Beck's Depression Inventory-II and Beck's Depression Inventory for Primary Care (BDI-PC). HR-QOL was evaluated using the Short Inflammatory Bowel Disease Questionnaire. Simple and multiple regressions were performed on quality of life score with demographic and clinical variables as predictors. RESULTS: The prevalence of depression in our study population is 25%. In patients with both CD and UC, depression is the most significant predictor to a poor HR-QOL (in CD, P = 8.22 × 10; in UC, P = 2.02 × 10). HR-QOL is weakly affected by disease activity (in CD, P = 0.110; in UC, P = 0.00492). In CD, biological use displays positive effect on HR-QOL (P = 0.00780). In total, the proportion of variance explained by all predictors is 61% for CD and 53% for UC, whereas the depression alone explains 44% and 36%. CONCLUSIONS: Our study demonstrates the importance of depression toward the quality of life in patients with inflammatory bowel disease. The diagnosis of depression should be actively sought out and treated in outpatient inflammatory bowel disease practices.
BACKGROUND:Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract that significantly impacts the health-related quality of life (HR-QOL). A decreased HR-QOL has been demonstrated in patients with active disease compared with patients in remission. In this cross-sectional study, we examined the role of depression and disease activity as independent factors in predicting patient's HR-QOL. METHODS: Hundred and five patients with either Crohn's disease (CD) or ulcerative colitis (UC) were enrolled. Disease activity was evaluated using Crohn's Disease Activity Index or Seo's Activity Index. Depressive symptoms were evaluated using Beck's Depression Inventory-II and Beck's Depression Inventory for Primary Care (BDI-PC). HR-QOL was evaluated using the Short Inflammatory Bowel Disease Questionnaire. Simple and multiple regressions were performed on quality of life score with demographic and clinical variables as predictors. RESULTS: The prevalence of depression in our study population is 25%. In patients with both CD and UC, depression is the most significant predictor to a poor HR-QOL (in CD, P = 8.22 × 10; in UC, P = 2.02 × 10). HR-QOL is weakly affected by disease activity (in CD, P = 0.110; in UC, P = 0.00492). In CD, biological use displays positive effect on HR-QOL (P = 0.00780). In total, the proportion of variance explained by all predictors is 61% for CD and 53% for UC, whereas the depression alone explains 44% and 36%. CONCLUSIONS: Our study demonstrates the importance of depression toward the quality of life in patients with inflammatory bowel disease. The diagnosis of depression should be actively sought out and treated in outpatientinflammatory bowel disease practices.
Authors: F Blondel-Kucharski; C Chircop; P Marquis; A Cortot; F Baron; J P Gendre; J F Colombel Journal: Am J Gastroenterol Date: 2001-10 Impact factor: 10.864
Authors: Magnus Simrén; Jenny Axelsson; Rolf Gillberg; Hasse Abrahamsson; Jan Svedlund; Einar S Björnsson Journal: Am J Gastroenterol Date: 2002-02 Impact factor: 10.864
Authors: Elspeth Guthrie; Judy Jackson; Jon Shaffer; David Thompson; Barbara Tomenson; Francis Creed Journal: Am J Gastroenterol Date: 2002-08 Impact factor: 10.864
Authors: Bharati Kochar; Edward L Barnes; Millie D Long; Kelly C Cushing; Joseph Galanko; Christopher F Martin; Laura E Raffals; Robert S Sandler Journal: Am J Gastroenterol Date: 2017-11-14 Impact factor: 10.864
Authors: Samantha Conley; Deborah D Proctor; Sangchoon Jeon; Robert S Sandler; Nancy S Redeker Journal: Res Nurs Health Date: 2017-08-17 Impact factor: 2.228
Authors: Edward L Barnes; Michael D Kappelman; Millie D Long; Donna M Evon; Christopher F Martin; Robert S Sandler Journal: Am J Gastroenterol Date: 2019-04 Impact factor: 10.864
Authors: Lawrence S Gaines; James C Slaughter; David A Schwartz; Dawn B Beaulieu; Sara N Horst; Robin L Dalal; Elizabeth A Scoville; Robert S Sandler; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2020-02-11 Impact factor: 5.325
Authors: Thiago H Freitas; Elias Andreoulakis; Gilberto S Alves; Hesley L L Miranda; Lúcia L B C Braga; Thomas Hyphantis; André F Carvalho Journal: World J Gastroenterol Date: 2015-06-07 Impact factor: 5.742
Authors: L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel Journal: Am J Gastroenterol Date: 2015-08-25 Impact factor: 10.864
Authors: Lawrence S Gaines; James C Slaughter; Sara N Horst; David A Schwartz; Dawn B Beaulieu; Kirsten L Haman; Li Wang; Christopher F Martin; Millie D Long; Robert S Sandler; Michael D Kappelman Journal: Am J Gastroenterol Date: 2016-04-05 Impact factor: 10.864